Filana Therapeutics, Inc.

FLNA Nasdaq SEC CIK 1069530
Follow Filana Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$10.7M +0.7% vs same quarter last year
EPS, diluted −$0.22 +0% vs same quarter last year
Operating cash flow −$6.1M +2% vs same quarter last year
Operating income −$11.3M +4.9% vs same quarter last year
Net income by quarter
−$27.6M
−$23.4M
−$44.2M
−$10.8M
−$12.5M
−$10.3M
−$8.6M
−$10.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$91M
FY24-−$24.3M
FY23-−$97.2M
FY22-−$76.2M
FY21-−$32.4M
FY20-−$6.3M
FY19-−$4.6M
FY18-−$6.6M
FY17-−$11.9M
FY16-−$14.9M
FY15-−$14.1M
FY14-−$12.4M
FY13$41.1M$31.5M
FY12$10.9M−$3.4M
FY11$11.5M−$2.6M
MarginsShare of revenue
  • Operating margin
  • Net margin
−50%0%50%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23--
FY22--
FY21--
FY20--
FY19--
FY18--
FY17--
FY16--
FY15--
FY14--
FY1376.3%76.7%
FY12−35.8%−31.6%
FY11−30.6%−22.8%
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$32.8M
FY24−$117M
FY23−$82.4M
FY22−$80.2M
FY21−$52.4M
FY20-
FY19−$2.5M
FY18-
FY17-
FY16−$12.3M
FY15−$9.2M
FY14−$9.6M
FY13-
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Filana Therapeutics
  • Healthcare median
−100%−50%0%50%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFilana TherapeuticsHealthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22-−80.4%
FY21-−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−37.8%
FY14-−35.5%
FY1376.7%−37.1%
FY12−31.6%−29.1%
FY11−22.8%−27.9%